Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

Authors: C. van Marcke, N. Honoré, A. van der Elst, S. Beyaert, F. Derouane, C. Dumont, F. Aboubakar Nana, J. F. Baurain, I. Borbath, P. Collard, F. Cornélis, A. De Cuyper, F. P. Duhoux, B. Filleul, R. Galot, M. Gizzi, F. Mazzeo, T. Pieters, E. Seront, I. Sinapi, M. Van den Eynde, N. Whenham, J. C. Yombi, A. Scohy, A. van Maanen, J. P. Machiels

Source: BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)

Subject Terms: Systemic anti-cancer treatment, Non-severe COVID-19, Ambulatory, Safety, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/95bcb44e832f4789979432b41c90aaa4